Clinical Trials

Thyroid cancer

NCT04211337 A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) ITALY
NCT01586520 Diagnosing Thyroid Cancer Using a Blood Test UK
NCT01089335 Sentinel Lymphnode in Patients With Papillary Thyroid Carcinoma and in Patients With Suspected Thyroid Neoplasia SWEDEN
NCT01265381 Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot Study UKRAINE
NCT01625520 SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer ITALY
NCT01788982 Nintedanib(BIBF1120) in Thyroid Cancer FRANCE/ITALY
NCT02268734 Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer Patients and Correlation With Vandetanib ITALY
NCT00181168 Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer FRANCE
NCT00786552 Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer GERMANY
NCT01774279 interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT) IRELAND/UK
NCT01398085 IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients UK
NCT02156362 Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis) FRANCE
NCT01403324 Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer FRANCE
NCT01843062 Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer DENMARK, FRANCE, GERMANY, ITALY, POLAND, SWEDEN
NCT02088645 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer. SWITZERLAND
NCT01896479 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer SWEDEN
NCT01704586 I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer GERMANY
NCT02390934 Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer FRANCE
NCT00339716 Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Belarus Following the Chernobyl Accident BELARUS
NCT01837745 Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? FRANCE
NCT01945762 Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer BELGIUM, FRANCE, GERMANY, ITALY, LUXEMBOURG, NETHERLANDS, SPAIN, UK
NCT02225509 Clinical Validation of a Molecular Signature to Detect Cancer in Thyroid Nodules With Indeterminate Cytology FRANCE, ITALY, SPAIN
NCT00749697 Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases UK
NCT01830504 A Multicenter Phase II Pilot Open Label FRANCE
NCT01813136 Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma FRANCE
NCT01118065 Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer NETHERLANDS
NCT01730638 ImmunoTEP for Patients With Medullary Thyroid Carcinoma. FRANCE
NCT02432274 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies FRANCE, GERMANY, ITALY, SPAIN, UK



Thyroid Cancer
A Phase III Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer. Verified January 2012 by Eisai Inc.
EISAI Protocol (PDF)

Summaries of EUGOGO Studies
Tabella Study B (PDF), Tabella Study C (PDF)

A multicentre randomised trial of high versus low dose radioiodine, with or without rhTSH, for remnant ablation following surgery for thyroid cancer. Chief Investigator: Dr Ujjal Mallick and Dr Clive Harmer
HiLo Summary (PDF)